Results Show Narrower Losses but Tight Funding

Fusion Antibodies (LSE:FAB), the Belfast-based antibody services provider, reported a narrower loss for the year to 31 March 2026 as it began commercialising its OptiMAL platform. Final results published on 14 September 2026 showed revenue edging higher and a sharp improvement in gross margin, but the directors also flagged a material uncertainty over going concern, saying further funding is expected to be needed. Chief executive Adrian Kinkaid called FY2026 "another year of important progress".

What the Company Does

Fusion was spun out of Queen's University Belfast in 2001. It provides antibody discovery, engineering, production and optimisation services to pharmaceutical and biotechnology customers developing therapeutic and diagnostic products. Its OptiMAL technology is a platform designed to support antibody discovery and was commercially launched in December 2025 after validation work with the US National Cancer Institute.

Latest Developments

Revenue rose about 7% to £2.1m from £1.97m. However, underlying service revenue fell about 5% to £1.86m, with the balance coming from a one-off £250,000 sale of intellectual property to Finn Therapeutics. Management pointed to improving service revenue in the second half and growing engagement from larger customers.

Since the year end, patent protection for OptiMAL has advanced in Japan, Canada and Australia. The company is also continuing a DR5 therapeutic antibody programme with Queen's University Belfast. Other operating income of £872,000 came mainly from the Future Medicines Institute grant programme, while R&D spending increased to £861,000, largely on OptiMAL validation.

Financial Picture

Gross margin improved to 53% from 22%. The operating loss narrowed to £1.13m from a restated £1.63m, and the loss for the year was about £1.15m. Cash stood at £1.04m at the year end, up from £0.36m, helped by a fundraise in January 2026. The company does not pay a dividend.

The going concern disclosure is significant. The directors said additional funding is expected to be required within the assessment period, although it has not yet been committed. The chairman also warned that difficult market conditions were weighing on performance in the first half of FY27.

Sector and Index Context

Fusion is one of the smaller life sciences companies in the FTSE AIM All Share Index. Outsourced laboratory service providers serving early-stage biotech have faced a difficult few years, as tighter venture funding led many clients to cut or delay discovery work. Larger pharmaceutical customers offer more stable demand but tend to have longer sales cycles. Small AIM-quoted life sciences companies often depend on periodic share raises to bridge the gap to profitability, and share prices can be volatile around fundraisings.

Key Risks

The main risk is funding. With modest cash and a going concern uncertainty, the company is likely to need fresh capital, which could dilute existing shareholders. Revenue is small and can be lumpy, depending on a limited number of projects. Commercial uptake of OptiMAL is at an early stage, and competition from larger antibody discovery providers is intense. A prolonged slowdown in biotech spending would also affect demand.

What to Watch Next

Investors will look for news of any fundraising or partnership that addresses the funding requirement, early commercial contracts for OptiMAL, and further patent grants. A first-half trading update for the six months to 30 September 2026 would show whether the challenging conditions highlighted by the chairman have persisted. Progress on the DR5 programme could also provide longer-term upside if it attracts a development partner.